

Aziyo Biologics, Inc.
12510 Prosperity Drive, Suite 370
Silver Spring, MD 250904

September 7, 2022

Via EDGAR

Securities and Exchange Commission
Division of Corporation Finance
Office of Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: **Aziyo Biologics, Inc.**
Registration Statement on Form S-3
Filed August 31, 2022
File No. 333-267197

To whom it may concern:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Aziyo Biologics, Inc. (the "***Company***") hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-267197) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on September 8, 2022 or as soon as practicable thereafter.

* * * *

The Company requests that we be notified of such effectiveness by a telephone call to Wesley C. Holmes of Latham & Watkins LLP at (617) 948-6027 and that such effectiveness also be confirmed in writing.

Very truly yours,

Aziyo Biologics, Inc.

By: /s/ Matthew Ferguson
Matthew Ferguson
Chief Financial Officer

cc: Wesley C. Holmes, Latham & Watkins LLP
